Kaitland Shuster
Psychiatric/Mental Health · North Huntingdon, PANPI 1215459359
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,400 of the $20,436 with a category attached, or 65.6%. AbbVie accounts for 88.2% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $7,164, more than ten times the $476 reported in 2021. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 457 payments — averaging $44.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$451
- Alkermes, Inc.$419
- Teva Pharmaceuticals USA, Inc.$324
- Otsuka America Pharmaceutical, Inc.$288
- Supernus Pharmaceuticals, Inc.$179
- plus $744 from 13 others
What the payments were for
- Speaking & faculty fees$13,40066%
- Travel & lodging$4602%
- Food & beverage$6,52932%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 326 | $18,031 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $451 |
| Alkermes, Inc. | 21 | $419 |
| Teva Pharmaceuticals USA, Inc. | 20 | $324 |
| Otsuka America Pharmaceutical, Inc. | 14 | $288 |
| Supernus Pharmaceuticals, Inc. | 6 | $179 |
| Ironshore Pharmaceuticals Inc. | 8 | $159 |
| Vanda Pharmaceuticals Inc. | 6 | $138 |
| Neurocrine Biosciences, Inc. | 5 | $85 |
| Corium, LLC | 6 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Collegium Pharmaceutical, Inc. | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Lundbeck LLC | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Merck | 1 | $19 |
| Sobi, Inc | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$14,126
How this compares
$20,436 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 85 | $118,218 |
| RexultiBrexpiprazole | 12 | $16,107 |
| Vilazodone Hcl | 52 | $5,835 |
| Duloxetine Hcl | 46 | $1,503 |
| Ziprasidone Hcl | 13 | $1,171 |
| Valproic AcidValproic Acid (As Sodium Salt) | 12 | $785 |
| Perphenazine | 16 | $785 |
| Hydroxyzine Hcl | 64 | $688 |
| Sertraline Hcl | 90 | $672 |
| Quetiapine Fumarate | 62 | $663 |
| Oxcarbazepine | 16 | $659 |
| Aripiprazole | 42 | $588 |
| Buspirone Hcl | 79 | $560 |
| Trazodone Hcl | 62 | $524 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 54 | $513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $18,031 | $118,21885 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $288 | $16,10712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in North Huntingdon
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.